Submit Your Brexit-Related Changes Before We Move: EMA Plea To Industry
Executive Summary
A continuous two-way dialogue on Brexit between the European Medicines Agency and industry is a must. The EMA is tentatively planning three Brexit-related events for stakeholders and, in the meantime, it wants companies to keep it abreast of their plans for products affected by the UK’s departure from the EU
You may also be interested in...
Brexit: Number Of Drugs At Risk Of Shortage Cut From 108 to 39
The European Medicines Agency plans to work directly with the marketing authorization holders of products that are still at risk of supply shortages to address the outstanding issues.
EMA’s Request For Extra Staff Rebuffed As Losses ‘Worsen Dramatically’
Although the European Medicines Agency is predicting even greater staff attrition as the Brexit date nears, it has been told that it cannot have an extra 40 contract personnel to take on the growing workload.
'Fund it properly or it will implode': parting comments from Aginus Kalis on EU drug regulatory network
“If you don’t finance it correctly, it will implode.” This was the stark warning key European drug regulator Aginus Kalis gave about the European drug regulatory network in an exclusive interview to Scrip Regulatory Affairs on his last day as executive director of the Dutch Medicines Evaluation Board.